Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors JiSook Kim, InHwan Bae, JaeYul Choi, MinJeong Kim, JooYun Byun, MiJin Moon, EunYoung Lee, Yu-Yon Kim, Hyun Jeong Kang, Eunyoung Kim, SunYoung Jung, YoungGil Ahn, YoungHoon Kim, Kwee Hyun Suh
Title HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia
Journal Vol Issue Date Pages Journal Short Title
URL https://cancerres.aacrjournals.org/content/79/13_Supplement/1293
Abstract Text Cancer Res 2019;79(13 Suppl):Abstract nr 1293

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Tuspetinib Tuspetinib 4 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
Tuspetinib HM-43239|HM 43239|HM43239 FLT3 Inhibitor 66 Tuspetinib (HM43239) inhibits both wild-type and mutant FLT3, resulting in decreased activation of downstream signaling, and potentially leading to increased apoptosis and decreased proliferation of tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1293).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins FLT3 F691L hematologic cancer predicted - sensitive Tuspetinib Preclinical Actionable In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and F691L in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). detail...
FLT3 exon 14 ins FLT3 D835Y hematologic cancer predicted - sensitive Tuspetinib Preclinical Actionable In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and D835Y in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). detail...